Item 2.02. |
Results of Operations and Financial Condition. |
The information regarding noncash charges for impairment of goodwill and in-process R&D indefinite-lived intangible assets included in Item 2.06 below is incorporated into this Item 2.02 by reference.
As a result of the Company’s annual impairment analysis, the management of Cibus, Inc. (the “Company”) has determined that its goodwill and in-process R&D indefinite-lived intangible assets were impaired by an estimated $150.4 million and an estimated $99.0 million, respectively, for the year ended December 31, 2023. Accordingly, management expects to record a non-cash impairment charge of an estimated approximately $249.4 million for impairment of goodwill and in-process R&D indefinite-lived intangible assets in the consolidated financial statements for the year ended December 31, 2023.
The impaired assets were acquired in the merger transactions with Cibus Global, LLC in 2023. The Company’s impairment determination was based on the Company’s annual impairment testing of goodwill and other intangible assets in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 350, “Intangibles—Goodwill and Other” conducted in connection with the ongoing preparation of the financial statements to be included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
The Company began its annual impairment test by performing an assessment of qualitative factors, including macro-economic conditions, a decline in the Company’s stock price, progress on development activities, and overall financial performance. Based on its assessment of qualitative factors, the Company concluded it was more likely than not that the fair value of its reporting unit was less than its carrying value. Therefore, the Company performed a quantitative analysis and determined that the fair value of each of goodwill and in-process R&D indefinite-lived intangible assets was less than its respective carrying value.
All of the impairment charges are non-cash charges, and the Company does not expect to be required to make any current or future cash expenditures as a result of these impairments.
The Company has not completed the preparation of its financial statements for the fourth quarter or the fiscal year ended December 31, 2023. Accordingly, the noncash charges for impairment of goodwill and in-process R&D indefinite-lived intangible assets provided here are preliminary estimates and unaudited and are thus subject to change as the Company completes its financial results. BDO USA, P.C. has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary estimated financial data included in this report.
Forward-Looking Statements
This Current Report on Form 8-K contains “forward-looking statements” within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact included herein, including statements regarding Cibus’ operational and financial performance are forward-looking statements. Forward-looking statements may be identified by words such as “estimates,” “expect,” “could,” and “will,” or the negative of these and similar expressions.
These forward-looking statements are based on the current expectations and assumptions of Cibus’ management about future events, which are based on currently available information. These forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and beyond the control of Cibus. Cibus’ actual results could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to the completion of Cibus’ closing procedures with respect to its annual financial statements and the completion of the audit by Cibus’ independent registered public accounting firm of such financial statements; and other important factors discussed in “Risk Factors of Cibus, Inc.” filed as Exhibit 99.3 with Cibus’ Current Report on Form 8-K, which was filed with the